Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
SELLAS Life Sciences (SLS) Announces 15.85M Share Offering at $1.325/sh
-
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
-
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
-
SELLAS Life Sciences (SLS) Announces 3.65M Share Offering at $1.095/sh
-
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
-
SELLAS Life Sciences Group (SLS) PT Raised to $21 at Maxim Group, Following Clinical Business Update
-
SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th
-
SELLAS Life Sciences (SLS) Prices 2.32M Share Registered Direct Offering at $7/Sh
-
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
-
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market
-
SELLAS Life Sciences (SLS) Prices $6.5M Registered Direct Share Offering Priced At-The-Market
-
SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market
-
Maxim Group Upgrades SELLAS Life Sciences Group (SLS) to Buy
-
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results
-
SELLAS Life Sciences Announces Closing of $15 Million Public Offering
-
SELLAS Life Sciences (SLS) Prices $15 Million Public Offering of Common Stock, Warrants
-
SELLAS Life Sciences Announces Pricing of $15 Million Public Offering
-
Maxim Group Downgrades SELLAS Life Sciences Group (SLS) to Hold
-
SELLAS Life Sciences Announces Closing of $24.2 Million Public Offering
-
SELLAS Life Sciences (SLS) Prices Upsized $24.2 Million Public Offering of Common Stock, Warrants
-
SELLAS Life Sciences Announces Pricing of Upsized $24.2 Million Public Offering
-
UPDATE: Maxim Group Upgrades SELLAS Life Sciences Group (SLS) to Buy

